Beyond PD-L1, when would you consider additional molecular testing (EGFR, ALK1, ROS1) for patients with squamous cell lung cancers?

I mainly test patients with squamous cell lung cancer if they are never, remote or light smokers, or if the diagnosis was based on a small biopsy and pathologist was not 100% sure squamous cell was the histology. Other experts would argue to test all patients regardless of histology for mutations as...